News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
BENNETT C FRANK
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/29/2023 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 4,460 shares
@ $46.5, valued at
$207.4k
|
|
03/02/2023 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Acquired 383 shares
@ $30.515, valued at
$11.7k
|
|
02/07/2023 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Granted 3,609 shares
@ $0 Sold 1,813 shares
@ $40.5738, valued at
$73.6k
|
|
01/19/2023 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 6,978 shares
@ $38.8874, valued at
$271.4k
Exercised 19,417 restricted stock units
@ $0 |
|
01/18/2023 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Granted 13,656 options to buy
@ $0 Granted 16,387 options to buy
@ $0 |
|
01/05/2023 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Granted 21,849 options to buy
@ $37.58, valued at
$821.1k
|
|
09/01/2022 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Acquired 183 shares
@ $28.968, valued at
$5.3k
|
|
03/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/20/2022 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Paid exercise price by delivering 6,726 shares
@ $30.12, valued at
$202.6k
Exercised 18,842 restricted stock units
@ $0 |
|
01/19/2022 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Granted 10,826 options to buy
@ $0 Granted 14,435 options to buy
@ $0 |
|
01/05/2022 |
4
| BENNETT C FRANK (EVP, Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Granted 28,869 options to buy
@ $32.6, valued at
$941.1k
|
|
09/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/08/2020 |
4
| BENNETT C FRANK (Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 7,947 shares
@ $51.04, valued at
$405.6k
Exercised 7,947 options to buy
@ $39.87, valued at
$316.8k
|
|
12/04/2020 |
4
| BENNETT C FRANK (Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 7,053 shares
@ $51.32, valued at
$362k
Exercised 7,053 options to buy
@ $39.87, valued at
$281.2k
|
|
11/05/2020 |
4
| BENNETT C FRANK (Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 15,000 shares
@ $46.7733, valued at
$701.6k
Exercised 15,000 options to buy
@ $39.87, valued at
$598.1k
|
|
09/02/2020 |
4
| BENNETT C FRANK (Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Acquired 112 shares
@ $44.455, valued at
$5k
|
|
06/29/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/17/2020 |
4
| BENNETT C FRANK (Chief Scientific Officer) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Paid exercise price by delivering 4,162 shares
@ $62.06, valued at
$258.3k
Granted 21,612 restricted stock units
@ $0 Exercised 11,711 restricted stock units
@ $0 |
|
01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/02/2019 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Acquired 118 shares
@ $45.7045, valued at
$5.4k
|
|
02/05/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/17/2019 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Paid exercise price by delivering 2,818 shares
@ $58.26, valued at
$164.2k
Granted 20,797 restricted stock units
@ $0 Exercised 7,822 restricted stock units
@ $0 |
|
01/03/2019 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Acquired 128 shares
@ $36.448, valued at
$4.7k
Granted 46,800 options to buy
@ $53.77, valued at
$2.5M
|
|
11/01/2018 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 12,500 shares
@ $49.5396, valued at
$619.2k
Exercised 12,500 options to buy
@ $14.69, valued at
$183.6k
|
|
08/09/2018 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 13 shares
@ $45, valued at
$585 Sold 12,487 shares
@ $45, valued at
$561.9k
Exercised 13 options to buy
@ $7.25, valued at
$94.3 Exercised 12,487 options to buy
@ $14.69, valued at
$183.4k
|
|
07/03/2018 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Acquired 282 shares
@ $35.4195, valued at
$10k
|
|
05/11/2018 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 12,500 shares
@ $45, valued at
$562.5k
Exercised 12,500 options to buy
@ $7.25, valued at
$90.6k
|
|
01/17/2018 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Sold 2,696 shares
@ $51.76, valued at
$139.5k
Granted 12,137 restricted stock units
@ $0 Exercised 6,663 restricted stock units
@ $0 |
|
01/02/2018 |
4
| BENNETT C FRANK (SVP, Antisense Research) has filed a Form 4 on IONIS PHARMACEUTICALS INC
Txns:
| Acquired 106 shares
@ $42.755, valued at
$4.5k
Granted 54,619 options to buy
@ $49.25, valued at
$2.7M
|
|
10/20/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|